Literature DB >> 20045993

Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.

Hiromi Fukushima-Uesaka1, Yoshiro Saito, Keiko Maekawa, Kouichi Kurose, Emiko Sugiyama, Noriko Katori, Nahoko Kaniwa, Ryuichi Hasegawa, Tetsuya Hamaguchi, Takako Eguchi-Nakajima, Ken Kato, Yasuhide Yamada, Yasuhiro Shimada, Teruhiko Yoshida, Noboru Yamamoto, Hiroshi Nokihara, Hideo Kunitoh, Yuichiro Ohe, Tomohide Tamura, Takashi Ura, Miyuki Saito, Kei Muro, Toshihiko Doi, Nozomu Fuse, Takayuki Yoshino, Atsushi Ohtsu, Nagahiro Saijo, Yasuhiro Matsumura, Haruhiro Okuda, Jun-ichi Sawada.   

Abstract

ATP7A and ATP7B are involved in cellular resistance to platinum compounds such as cisplatin. By sequencing ATP7A, 38 genetic variations, including 30 novel ones were detected from 203 Japanese cancer patients. Of these, seven nonsynonymous variations were found: novel 1030A>G (R344G), 2111A>G (Q704R), 2200C>A (Q734K), 2948C>T (T983M) and 3112G>A (V1038I) at 0.004 frequencies and known 2299G>C (V767L) and 4390A>G (I1464V) at 0.351 and 0.075 frequencies, respectively. Regarding ATP7B, 28 novel and 33 known genetic variations were detected including 13 nonsynonymous ones: novel 1258A>G (M420V), 1426G>A (A476T), and 2401A>C (T801P) were found at 0.002, 0.005, and 0.002, respectively and known 1216G>T (A406S), 1366G>C (V456L), 2495A>G (K832R), 2785A>G (I929V), 2855G>A (R952K), 2871delC (P957PfsX9), 3419T>C (V1140A), 3836A>G (D1279G), 3886G>A (D1296N) and 3889G>A (V1297I) at 0.483, 0.463, 0.387, 0.005, 0.384, 0.005, 0.387, 0.002, 0.012, and 0.015 frequencies, respectively. Linkage disequilibrium between detected variations was also analyzed. Our results would provide fundamental and useful information for genotyping ATP7A and ATP7B in the Japanese and probably other Asian populations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20045993     DOI: 10.2133/dmpk.24.565

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  8 in total

1.  Functional consequences of PRPF39 on distant genes and cisplatin sensitivity.

Authors:  Amy L Stark; Shannon M Delaney; Heather E Wheeler; Hae Kyung Im; M Eileen Dolan
Journal:  Hum Mol Genet       Date:  2012-07-05       Impact factor: 6.150

2.  The ATP7B genetic polymorphisms predict clinical outcome to platinum-based chemotherapy in lung cancer patients.

Authors:  Xiang-Ping Li; Ji-Ye Yin; Ying Wang; Hui He; Xi Li; Wei-Jing Gong; Juan Chen; Chen-Yue Qian; Yi Zheng; Fang Li; Tao Yin; Zhi-Cheng Gong; Bo-Ting Zhou; Yu Zhang; Ling Xiao; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Tumour Biol       Date:  2014-05-23

Review 3.  DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors:  S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal:  Curr Cancer Drug Targets       Date:  2012-05       Impact factor: 3.428

Review 4.  Polymorphic transporters and platinum pharmacodynamics.

Authors:  Jason A Sprowl; Rachel A Ness; Alex Sparreboom
Journal:  Drug Metab Pharmacokinet       Date:  2012-09-18       Impact factor: 3.614

Review 5.  Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer.

Authors:  Maimon C Rose; Elina Kostyanovskaya; R Stephanie Huang
Journal:  Genomics Proteomics Bioinformatics       Date:  2014-10-28       Impact factor: 7.691

Review 6.  Genetic determinants for chemo- and radiotherapy resistance in bladder cancer.

Authors:  Andrea Mari; David D'Andrea; Mohammad Abufaraj; Beat Foerster; Shoji Kimura; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2017-12

7.  Cuproptosis-Related Gene - SLC31A1, FDX1 and ATP7B - Polymorphisms are Associated with Risk of Lung Cancer.

Authors:  Yuhui Yun; Yun Wang; Ende Yang; Xin Jing
Journal:  Pharmgenomics Pers Med       Date:  2022-07-26

8.  An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury.

Authors:  Stuart M Robinson; Jelena Mann; Derek M Manas; Derek A Mann; Steven A White
Journal:  HPB (Oxford)       Date:  2012-12-27       Impact factor: 3.647

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.